Pfizer-BioNTech COVID-19 vaccine

BIOLOGICAL5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Sunnybrook Health Sciences Centre, Respiralab, Providence Therapeutics Holdings Inc., University of Oxford

Conditions

Adverse Drug EventAllergic ReactionCOVID-19Chronic Kidney DiseasesCovid-19 PandemicsCovid19 VaccineMast Cell DisorderSARS-CoV Infection

Phase 2

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

CompletedNCT04761822

National Institute of Allergy and Infectious Diseases (NIAID)Allergic Reaction, COVID-19, Mast Cell Disorder +1

Start: 2021-04-07End: 2022-04-27Updated: 2025-08-12

COVID-19 Vaccine Boosters in Patients With CKD

TerminatedNCT05022329

Sunnybrook Health Sciences CentreChronic Kidney Diseases, COVID-19

Start: 2021-09-30End: 2022-11-15Updated: 2025-02-19

PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.

CompletedNCT05175742

Providence Therapeutics Holdings Inc.Covid19 Vaccine

Start: 2021-08-17End: 2023-03-29Updated: 2023-04-07

Unknown Phase

Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers

CompletedNCT05113472

RespiralabAdverse Drug Event

Start: 2021-03-01End: 2021-05-31Updated: 2021-11-09

Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients

RecruitingNCT05571735

University of OxfordCovid-19 Pandemics, Tuberculosis

Start: 2023-04-15End: 2026-06-30Target: 133Updated: 2026-04-13

Related Papers

Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study

Scientific Reports2024-03-045 citations

BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients

Clinical Journal of the American Society of Nephrology2023-10-1711 citations

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

Blood Advances2022-01-2421 citations